{"id":"https://openalex.org/W2990445664","doi":"https://doi.org/10.1183/13993003.congress-2019.pa1398","title":"BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: A single/multiple ascending dose (SAD/MAD) phase 1 study","display_name":"BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: A single/multiple ascending dose (SAD/MAD) phase 1 study","publication_year":2019,"publication_date":"2019-09-28","ids":{"openalex":"https://openalex.org/W2990445664","doi":"https://doi.org/10.1183/13993003.congress-2019.pa1398","mag":"2990445664"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2019.pa1398","doi":"https://doi.org/10.1183/13993003.congress-2019.pa1398","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2019.pa1398","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rare ILD/DPLD","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044159184","display_name":"Giridhar Tirucherai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Giridhar Tirucherai","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, United States of America","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102376850","display_name":"Dale Yu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I920293368","display_name":"PRA Health Sciences","ror":"https://ror.org/02k5t6c64","country_code":"US","type":"facility","lineage":["https://openalex.org/I920293368"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dale Yu","raw_affiliation_strings":["PRA Health Sciences, Silverado, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PRA Health Sciences, Silverado, United States of America","institution_ids":["https://openalex.org/I920293368"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113921323","display_name":"Ratna Revankar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ratna Revankar","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, United States of America","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049232753","display_name":"George H. Klinger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George Klinger","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, United States of America","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055811263","display_name":"Jan Jaap van Lier","orcid":"https://orcid.org/0000-0001-9676-5136","observed_orcids":["https://orcid.org/0000-0001-9676-5136"]},"institutions":[{"id":"https://openalex.org/I920293368","display_name":"PRA Health Sciences","ror":"https://ror.org/02k5t6c64","country_code":"US","type":"facility","lineage":["https://openalex.org/I920293368"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jan Jaap Van Lier","raw_affiliation_strings":["PRA Health Sciences, Groningen, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PRA Health Sciences, Groningen, Netherlands","institution_ids":["https://openalex.org/I920293368"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083601745","display_name":"J\u00f6rg T\u00e4ubel","orcid":"https://orcid.org/0000-0002-0010-207X","observed_orcids":["https://orcid.org/0000-0002-0010-207X"]},"institutions":[{"id":"https://openalex.org/I165862685","display_name":"St George's, University of London","ror":"https://ror.org/040f08y74","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I165862685","https://openalex.org/I4401726869"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jorg Taubel","raw_affiliation_strings":["St George\u2019s University of London, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St George\u2019s University of London, London, United Kingdom","institution_ids":["https://openalex.org/I165862685"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050697666","display_name":"Todd A. Correll","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Todd Correll","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, United States of America","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA1398","last_page":"PA1398"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11308","display_name":"Sphingolipid Metabolism and Signaling","score":0.44749999046325684,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11308","display_name":"Sphingolipid Metabolism and Signaling","score":0.44749999046325684,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10870","display_name":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","score":0.4246000051498413,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.004999999888241291,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lysophosphatidic-acid","display_name":"lysophosphatidic acid","score":0.9319999814033508},{"id":"https://openalex.org/keywords/idiopathic-pulmonary-fibrosis","display_name":"idiopathic pulmonary fibrosis","score":0.9610000252723694},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9240000247955322},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.906000018119812},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.6710000038146973},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.7490000128746033},{"id":"https://openalex.org/keywords/blood-pressure-reduction","display_name":"blood pressure reduction","score":0.8259999752044678},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6539999842643738},{"id":"https://openalex.org/keywords/multiple-ascending-dose","display_name":"multiple ascending dose","score":0.6930000185966492},{"id":"https://openalex.org/keywords/single-ascending-dose","display_name":"single ascending dose","score":0.9629999995231628},{"id":"https://openalex.org/keywords/dose-limiting-adverse-events","display_name":"dose-limiting adverse events","score":0.7850000262260437},{"id":"https://openalex.org/keywords/liver-function","display_name":"liver function","score":0.5220000147819519}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.872771143913269},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.616278886795044},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5978188514709473},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5881205201148987},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5670735836029053},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.551903486251831},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5425631999969482},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.5062031149864197},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4270630180835724},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.4246659576892853},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.41987815499305725},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.39412468671798706},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3783642053604126},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37702804803848267},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2790239453315735},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.12390303611755371},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2019.pa1398","doi":"https://doi.org/10.1183/13993003.congress-2019.pa1398","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2019.pa1398","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rare ILD/DPLD","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3041539130","https://openalex.org/W4367606467","https://openalex.org/W7161552912","https://openalex.org/W4404104301","https://openalex.org/W4200203068","https://openalex.org/W3096197860","https://openalex.org/W2776350037","https://openalex.org/W4387982302","https://openalex.org/W2891745120","https://openalex.org/W4396502843"],"abstract_inverted_index":{"Introduction:":[0],"The":[1,80],"LPA1":[2,15],"receptor":[3,16],"is":[4,10,39,246,256],"implicated":[5],"in":[6,33,48,142,157,162,177,254],"IPF":[7,255],"pathogenesis.":[8],"BMS-986278":[9,32,59,96,119,128,138,224,227],"a":[11,40,198,207],"potent":[12],"small":[13],"molecule":[14],"antagonist":[17],"being":[18],"investigated":[19],"for":[20,100],"IPF.":[21],"This":[22],"study":[23,47,251],"evaluated":[24],"the":[25,150],"safety,":[26],"tolerability,":[27],"and":[28,73,120,129,139,144,164,167,186,192,244],"PK":[29,241],"of":[30,200,252],"oral":[31],"healthy":[34,49],"participants":[35],"(ppts).":[36],"Methods:":[37],"IM027-009":[38],"phase":[41],"1,":[42],"double-blind,":[43],"placebo":[44],"(PBO)-controlled,":[45],"randomized":[46],"adults.":[50],"In":[51,91,183],"SAD":[52,82,143,163,185],"evaluation":[53],"(with":[54],"sentinel":[55],"dosing),":[56],"ppts":[57,94,117,126],"received":[58,95,118,122,127,131],"or":[60,70,97,106,108,112],"PBO":[61,98,140],"(6:2)":[62,99],"at":[63,102],"doses":[64,103],"3,":[65],"10,":[66],"30,":[67],"100,":[68],"150,":[69],"250mg;":[71],"food":[72],"pH":[74,218],"effects":[75],"were":[76,135,148,160,168,181,235],"analyzed":[77],"with":[78,171,197,213],"100mg.":[79],"250-mg":[81],"was":[83,154,204,228,242],"terminated":[84],"due":[85],"to":[86],"dose-limiting":[87],"AEs":[88,147],"(sentinel":[89],"cohort).":[90],"MAD":[92,165,187],"evaluation,":[93],"14d":[101],"QD":[104],"(10":[105],"30mg)":[107],"BID":[109],"(30,":[110],"60,":[111],"125mg).":[113],"Results:":[114],"SAD:":[115],"37":[116],"11":[121],"PBO;":[123],"MAD:":[124],"30":[125],"10":[130],"PBO.":[132],"Baseline":[133],"demographics":[134],"similar":[136],"between":[137],"groups":[141],"MAD.":[145],"Most":[146],"mild;":[149],"most":[151],"common":[152],"AE":[153],"headache.":[155],"Decreases":[156],"blood":[158,232],"pressure":[159,233],"seen":[161,243],"cohorts":[166],"not":[169],"associated":[170],"discontinuation.":[172,239],"No":[173],"clinically":[174],"significant":[175],"elevations":[176],"liver":[178],"function":[179],"tests":[180],"seen.":[182],"both":[184],"cohorts,":[188],"BMS":[189],"986278":[190],"Cmax":[191],"AUC":[193],"appeared":[194],"dose":[195],"proportional":[196],"half-life":[199],"approximately":[201],"10h;":[202],"Tmax":[203],"slower":[205],"after":[206],"high-fat":[208],"meal":[209],"vs":[210],"fasted":[211],"state":[212],"no":[214,220],"exposure":[215],"difference.":[216],"Gastric":[217],"had":[219],"notable":[221],"effect":[222],"on":[223],"PK.":[225],"Conclusions:":[226],"generally":[229],"well":[230],"tolerated;":[231],"reductions":[234],"reported":[236],"without":[237],"treatment":[238],"Dose-proportional":[240],"dosing":[245],"supported":[247],"with/without":[248],"food.":[249],"Further":[250],"BMS\u2011986278":[253],"warranted.":[257]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3}],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2019-12-05T00:00:00"}